Important new study in POTS! Dr. Taub's team at @UCSDMedSchool found that ivabradine reduces heart rate and plasma norepineprhine, and improves quality of life in POTS. We hope this will help patients have greater access to this treatment, because many insurers deny it. https://t.co/j8sF2zAswu

— Dysautonomia Intl. (@Dysautonomia) February 15, 2021